General：Sunitinib malate is a novel oral multi-target anti-tumor drug, belonging to the category of multi-target tyrosine kinase inhibitors. It has dual anti-tumor and anti angiogenic effects and holds a core position in the treatment of renal cell carcinoma and gastrointestinal stromal tumors.

Product introduce：Sunitinib Malate (SU11248) is a multi-target RTK inhibitor that acts on VEGFR2 (Flk-1) and PDGFR β， It will inhibit the activity of c-Kit. Can effectively inhibit Ire1 α The self phosphorylation of increases death receptor and mitochondrial dependent cell apoptosis.

Function：Sunitinib plays a therapeutic role by preventing tumor cells from obtaining the necessary blood and nutrients for growth. Clinical trials have shown that this drug can slow down the growth rate of gastrointestinal stromal tumors and reduce the size of renal cell tumors.

      Origin：Developed by Pfizer in the United States, it has a dual anti-tumor effect and is the only therapeutic drug that breaks through the 2-year survival period of advanced renal cell carcinoma. In February 2006, sunitinib malate was launched in the United States, which was the first anti-cancer drug approved by the US FDA to treat both diseases simultaneously.